CSRC asks Good Doctor Cloud to supplement HK filing on 10 issues
NewTimeSpace News: On November 20, 2026, the International Department of the China Securities Regulatory Commission (CSRC) said it issued supplementary filing requirements for overseas listings to 15 companies between November 16 and 20, 2026, including Sichuan Good Doctor Cloud Healthcare & Technology Group Co., Ltd. ("Good Doctor Cloud"). The company was asked to explain 10 areas covering its equity history, shareholder verification, business qualifications, full circulation arrangements and consistency of the maximum offering size, with its lawyers to verify the matters and issue clear legal opinions.
On equity and shareholders, the regulator sought the background and pricing fairness of Jianengda Investment's transfer of a 2.5% stake to Yang Changsheng in 2018 at RMB1 per unit of registered capital, and Yang's transfer of the same stake back to Jianengda Investment at the original price in 2020, together with the reasons why consideration for the second 2020 transfer and the 2023 transfer and capital increase was lower than concurrent levels. It also asked whether any nominee shareholding existed and whether the incorporation and successive equity changes of the issuer and its predecessor were lawful and compliant. The company must clarify whether Hong Kong Cloud Medical, Hengqin Guoyi Investment, Hengqin Cloud Medical and Jiayue Ruihe fall within Article 8 of the Trial Measures for the Administration of Overseas Securities Offering and Listing by Domestic Companies, and whether the actual controllers of employee shareholding platforms Gongchuang No. 1 and No. 2 are related to the controlling shareholder and actual controller, or should be deemed joint actual controllers. Other queries cover the relationships among Sanyi Sci-Tech Innovation Fund, Rongke Investment, Rongke Huizhi, Fengqi Wutong and Wutong Juhao and whether their stakes should be calculated on a combined basis, look-through checks on shareholders holding 5% or more, the fifth capital increase in 2024 and the reasons, transaction prices and pricing basis for new shareholders' subscriptions in the past 12 months, state-owned shareholder holdings, and the basis for counting Hangzhou Quanzhen Medical Technology Co., Ltd. as one shareholder.
On business, the CSRC asked for the functions and use scenarios of the Good Doctor payment settlement platform, the special smart supervision system for medical aesthetics and the Shangyimei intelligent supervision platform for medical aesthetics practices, to determine whether the issuer is involved in financial or medical aesthetics businesses, and for details of drug and medical device licences held by the issuer and its subsidiaries. On the offering, the company must disclose the number of shares under the full circulation plan, its proportion of pre-offering total share capital and the H-share proportion after the offering and full circulation, whether those shares are pledged, frozen or otherwise encumbered, the backgrounds and qualifications of Liu Jinbai, Sun Xiaobo and Cai Longjun, any material litigation or arbitration that would impede the listing, and the complete pre- and post-offering shareholding structure, including before and after the over-allotment option.
- ROKAE ROBOTICS (03752.HK): Plans A Share Listing on Shenzhen Exchange
- NEW HIGHER EDU (02001.HK): Sells Zhengzhou College for RMB 594 Million
- AKESO (09926.HK): Trustee Buys 150,000 Shares for HKD 8.5 Million
- GOLDSTONE CAP (01160.HK): Gives Up Review, Suspended from 23 Nov
- DOBOT (02432.HK): Trustee Buys 200,000 H Shares on Market